Perioperative optimization of the heart failure patient

International Anesthesiology Clinics

Volumn 47, Issue 4, 2009, Pages 121-135

  Wojciechowski, Paul ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIGENIN DIGITOXOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; METOPROLOL; SPIRONOLACTONE; CARDIOVASCULAR AGENT;

ANAMNESIS; BLOOD PRESSURE; BLOOD TESTIS BARRIER; CARDIOLOGIST; CLINICAL TRIAL; DEFIBRILLATOR; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HEART PERFORMANCE; HEART SURGERY; HUMAN; HYPERKALEMIA; LABORATORY TEST; LONG TERM CARE; MEDICAL SOCIETY; PERIOPERATIVE PERIOD; PHYSICAL EXAMINATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING; THORAX RADIOGRAPHY; VASOCONSTRICTION; VASODILATATION; CLASSIFICATION; NOMENCLATURE; POSTOPERATIVE CARE; PREOPERATIVE CARE;

CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RISK REDUCTION BEHAVIOR; TERMINOLOGY AS TOPIC;

EID: 73449110965     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e3181b47e88     Document Type: Review

References (46)

1. Lloyd-Jones D, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480-486.
2. Lloyd-Jones DM, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
3. DeFrances CJ, et al. 2006 National hospital discharge survey. Natl Health Stat Report. 2008:1-20.
4. Xu-Cai YO, et al. Outcomes of patients with stable heart failure undergoing elective noncardiac surgery. Mayo Clin Proc. 2008;83:280-288.
5. Hammill BG, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology. 2008;108:559-567.
6. Groban L, Butterworth J. Perioperative management of chronic heart failure. Anesth Analg. 2006;103:557-575.
7. Redfield MM, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289: 194-202.
8. Writing Committee Members, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119: e391-e479.
9. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393.
10. Jessup M, et al. Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009.
11. Dosh SA. Diagnosis of heart failure in adults. Am Fam Phys. 2004;70:2145-2152.
12. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628-640.
13. Practice advisory for preanesthesia evaluation: a report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology. 2002;96: 485-496.
14. Pfisterer M, et al. BNP-guided versus symptom-guided heart failure therapy: the Trial of Intensified versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-392.
15. Skaluba SJ, Litwin SE. Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation. 2004;109:972-977.
16. Pirracchio R, et al. Diastolic heart failure in anaesthesia and critical care. Br J Anaesth. 2007;98:707-721.
17. Yu CM, et al. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol. 2007;49:1903-1914.
18. Fleisher LA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50:1707-1732.
19. McFalls EO, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351:2795-2804.
20. Varin R, et al. Improvement of endothelial function by chronic angiotens in converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000;102:351-356.
21. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325: 293-302.
22. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
23. Cohn J, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
24. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-IS4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
25. Pfeffer M, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
26. Arnold JM, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:1284-1290.
27. Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
28. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
29. McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
30. Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
31. Granger CB, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
32. Mancia G, et al. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol. 1999;84:28S-34S.
33. MacDonald JM. Anaesthesia and angiotensin II receptor antagonist. Anaesthesia. 2000;55:1038.
34. Bertrand M, et al. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg. 2001;92:26-30.
35. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
36. Zannad F, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
37. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
38. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
39. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
40. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512-2518.
41. Schepkens H, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
42. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet. 1999;353:9-13.
43. Hjalmarson A, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-MERHF Study Group. JAMA. 2000;283:1295-1302.
44. Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199.
45. Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
46. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.